Takeda Pharmaceutical Co., Ltd. is a Japanese multinational pharmaceutical company with a rich history dating back over 230 years. The company was founded in 1781 by Chobei Takeda I in Osaka, Japan, as a small traditional medicine shop. Over the centuries, Takeda expanded its operations and evolved into a leading global pharmaceutical company.
Takeda's core focus is on the development and commercialization of pharmaceutical products to improve the health and well-being of patients worldwide. The company is involved in research and development across various therapeutic areas, including oncology, gastroenterology, neuroscience, rare diseases, and vaccines. Takeda's commitment to innovation has resulted in the creation of several groundbreaking therapies that have positively impacted the lives of millions of patients.
The company operates globally, with a strong presence in both developed and emerging markets. Takeda's headquarters is in Tokyo, Japan. It also has a significant presence in the United States and Europe, with multiple research and development centers and manufacturing facilities worldwide.
In 2019, Takeda made a significant acquisition by purchasing Irish pharmaceutical company Shire plc for approximately $62 billion. This acquisition expanded Takeda's global footprint and diversified its product portfolio, making it a major player in the rare disease and specialty pharmaceutical markets.